RAS testing in metastatic colorectal cancer: advances in Europe

Personalized medicine shows promise for maximizing efficacy and minimizing toxicity of anti-cancer treatment. KRAS exon 2 mutations are predictive of resistance to epidermal growth factor receptor-directed monoclonal antibodies in patients with metastatic colorectal cancer. Recent studies have shown...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Virchows Arch
Autors principals: Van Krieken, J Han JM, Rouleau, Etienne, Ligtenberg, Marjolijn J. L., Normanno, Nicola, Patterson, Scott D., Jung, Andreas
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2015
Matèries:
Review and Perspectives
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4830882/
https://ncbi.nlm.nih.gov/pubmed/26573425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00428-015-1876-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars